Oracle Hits Year Low as Another Cash Raise Fuels Dilution Concerns

What happened

Oracle's stock fell to around $115, its lowest level this year, after the company announced another equity raise to fund its AI infrastructure buildout, with shares now down over 52% from their all-time high. This move adds to the $19.9 billion ATM issuance already completed in Q1 FY2027, intensifying concerns about shareholder dilution while the company continues to burn cash on data centers and leases. Despite a massive $664 billion remaining performance obligation (RPO) backlog and strong cloud revenue growth, only 13% of that backlog converts within 12 months, leaving a funding gap that management is filling with debt and equity. The balance sheet remains stretched with net debt/EBITDA near 3.7x and interest coverage around 4.5x, leaving little room for execution missteps or further credit downgrades. The market is now pricing Oracle more as a leveraged AI infrastructure story with front-loaded costs and back-end-loaded revenue, and today's price reflects increasing skepticism about whether that model will deliver acceptable returns without further dilution.

Implication

Current shareholders should treat any bounce as an opportunity to reduce exposure if the next filing does not show clear improvement in customer prepayments, 12-month RPO conversion, or free cash flow. A conservative entry point is only justified if price approaches the bear case value around $95, which would require evidence of power delays or a credit downgrade below BBB-. The company's fundamental demand remains real, but per-share value is being eroded by dilution at a time when the stock is already down sharply. Until Oracle can fund its AI buildout with operating cash flow rather than equity issuance, the investment case remains unattractive for new capital. Monitor lease commencements and any signs that the large AI contracts are being renegotiated, as those would further validate the bear scenario.

Thesis delta

The WAIT rating from the DeepValue master report is unchanged, but the risk of further downside has increased. The new equity raise accelerates dilution and directly undermines per-share value at a time when the stock is already near the lower end of our scenario range. We would need to see sustained improvement in RPO conversion and a halt to equity issuance before considering the attractive entry point at $115 as a buying opportunity.